Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety

References

• WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19; 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020. Accessed 307 2020..
   Google Scholar
• AhmadA, RehmanMU, AlkharfyKM. An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections. Eur Rev Med Pharmacol Sci. 2020;24(7):4030–4034. doi:10.26355/eurrev_202004_2087332329879
   PubMed Web of Science ®Google Scholar
• GaoJ, HuS. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). Biosci Trends. 2020;14(2):156–158. doi:10.5582/bst.2020.0307232281583
   PubMed Web of Science ®Google Scholar
• ZhaoM. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020;55(6):105982. doi:10.1016/j.ijantimicag.2020.10598232305588
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. NIH U.S. National Library of Medicine; 2020. Available from: https://clinicaltrials.gov/ct2/results?cond=COVID+19&term=Hydroxychloroquine&cntry=&state=&city=&dist=&Search=Search. Accessed 307 2020..
   Google Scholar
• AggarwalG, HenryBM, AggarwalS, BangaloreS. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. Am J Cardiol. 2020;128:147–150. doi:10.1016/j.amjcard.2020.04.05432425199
   PubMed Web of Science ®Google Scholar
• BessièreF, RocciaH, DelinièreA, et al. Assessment of QT Intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.1787
   PubMed Web of Science ®Google Scholar
• LUPUS. Hydroxychloroquine: benefits, Side Effects, and Dosing; 2020. Available from: https://www.lupus.org/resources/drug-spotlight-on-hydroxychloroquine#:~:text=In%201941%2C%20discoid%20lupus%20patients,systemic%20lupus%20and%20rheumatoid%20arthritis. Accessed 307 2020..
   Google Scholar
• NCIthesarus. Hydroxychloroquine Sulfate (Code C29101); 2020. Available from: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C29101. Accessed 307 2020..
   Google Scholar
• FernerRE, AronsonJK. Chloroquine and hydroxychloroquine in covid-19. 2020. doi:10.1136/bmj.m1432
   Google Scholar
• VincentMJ, BergeronE, BenjannetS, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69. doi:10.1186/1743-422X-2-6916115318
   PubMed Web of Science ®Google Scholar
• NaksukN, LazarS, PeeraphatditTB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Hear Journal Acute Cardiovasc Care. 2020;9(3):215–221. doi:10.1177/2048872620922784
   PubMed Web of Science ®Google Scholar
• SinghAP, TousifS, UmbarkarP, LalH. A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: potential Implication in COVID-19 Mitigation. J Clin Med. 2020;9(6):1867. doi:10.3390/jcm9061867
   Web of Science ®Google Scholar
• NguyenLS, DolladilleC, DriciM-D, et al. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: an Analysis of the World Health Organization Pharmacovigilance Database. Circulation. 2020;142(3):303–305. doi:10.1161/CIRCULATIONAHA.120.04823832442023
   PubMed Web of Science ®Google Scholar
• Medscape. Hydroxychloroquine sulfate (Rx); 2020. Available from: https://reference.medscape.com/drug/plaquenil-hydroxychloroquine-sulfate-343205#4. Accessed 307 2020..
   Google Scholar
• GautretP, LagierJ-C, ParolaP, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi:10.1016/j.ijantimicag.2020.10594932205204
   PubMed Web of Science ®Google Scholar
• ChenJ, LiuD, LiuL, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ. 2020;49(1).
   Google Scholar
• MallatJ, HamedF, BalkisM, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. medRxiv. 2020.
   Google Scholar
• TangW, CaoZ, HanM, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. doi:10.1136/bmj.m184932409561
   PubMed Web of Science ®Google Scholar
• ChenZ, HuJ, ZhangZ, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020.
   Google Scholar
• RosenbergES, DufortEM, UdoT, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020;323(24):2493. doi:10.1001/jama.2020.863032392282
   PubMed Web of Science ®Google Scholar
• MagagnoliJ, NarendranS, PereiraF, et al. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID19. Med. 2020. doi:10.1016/j.medj.2020.06.001
   Web of Science ®Google Scholar
• GelerisJ, SunY, PlattJ, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–2418. doi:10.1056/NEJMoa201241032379955
   PubMed Web of Science ®Google Scholar
• YuB, LiC, ChenP, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020;1–7.
   PubMed Web of Science ®Google Scholar
• de NovalesFJM, Ramírez-OlivenciaG, EstébanezM, et al. Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study. Preprint. 2020.
   Google Scholar
• LeeJE, LeeSO, HeoJ, et al. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of coronavirus disease 2019 with mild to moderate severity. Preprint. 2020.
   Google Scholar
• MahévasM, TranV-T, RoumierM, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369.
   Google Scholar
• BarbosaJ, KaitisD, FreedmanR, LeK, LinX. Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19-a quasi-randomized comparative study. Bibliovid. 2020.
   Google Scholar
• MercuroNJ, YenCF, ShimDJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.1834
   PubMed Web of Science ®Google Scholar
• RamireddyA, ChughH, ReinierK, et al. Experience with Hydroxychloroquine and Azithromycin in the COVID‐19 Pandemic: implications for QT Interval Monitoring. J Am Heart Assoc. 2020;9:e017144.32463348
   PubMed Web of Science ®Google Scholar
• MehraMR, DesaiSS, RuschitzkaF, PatelAN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020.
   Web of Science ®Google Scholar
• US-FDA. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems; 2020. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or. Accessed 730, 2020..
   Google Scholar